These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9200464)

  • 21. Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques.
    Malenbaum SE; Yang D; Cheng-Mayer C
    J Virol; 2001 Oct; 75(19):9287-96. PubMed ID: 11533191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of hypervariable domains to the conformation of a broadly neutralizing glycoprotein 120 epitope.
    Lee CN; Robinson J; Mazzara G; Cheng YL; Essex M; Lee TH
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):777-81. PubMed ID: 7546903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.
    Azizi A; Anderson DE; Ghorbani M; Gee K; Diaz-Mitoma F
    BMC Immunol; 2006 Oct; 7():25. PubMed ID: 17076905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning.
    Tsui P; Tornetta MA; Ames RS; Bankosky BC; Griego S; Silverman C; Porter T; Moore G; Sweet RW
    J Immunol; 1996 Jul; 157(2):772-80. PubMed ID: 8752928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope.
    Buratti E; McLain L; Tisminetzky S; Cleveland SM; Dimmock NJ; Baralle FE
    J Gen Virol; 1998 Nov; 79 ( Pt 11)():2709-16. PubMed ID: 9820146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines.
    Coëffier E; Excler JL; Kieny MP; Meignier B; Moste C; Tartaglia J; Pialoux G; Salmon-Céron D; Leclerc C
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1471-85. PubMed ID: 9390746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.
    Lin G; Nara PL
    Curr HIV Res; 2007 Nov; 5(6):514-41. PubMed ID: 18045109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational instability governed by disulfide bonds partitions the dominant from subdominant helper T-cell responses specific for HIV-1 envelope glycoprotein gp120.
    Nguyen HN; Steede NK; Robinson JE; Landry SJ
    Vaccine; 2015 Jun; 33(25):2887-96. PubMed ID: 25944298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbohydrate targets in HIV vaccine research: lessons from failures.
    Pashov A; Garimalla S; Monzavi-Karbassi B; Kieber-Emmons T
    Immunotherapy; 2009 Sep; 1(5):777-94. PubMed ID: 20636023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus.
    Emini EA; Putney SD
    Biotechnology; 1992; 20():309-26. PubMed ID: 1600383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen.
    Haynes BF; Moody MA; Heinley CS; Korber B; Millard WA; Scearce RM
    AIDS Res Hum Retroviruses; 1995 Feb; 11(2):211-21. PubMed ID: 7742036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human T-helper cell recognition of an immunodominant epitope of HIV-1 gp120 expressed on the surface of Streptococcus gordonii.
    Pozzi G; Oggioni MR; Manganelli R; Medaglini D; Fischetti VA; Fenoglio D; Valle MT; Kunkl A; Manca F
    Vaccine; 1994 Sep; 12(12):1071-7. PubMed ID: 7998415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.
    Tian J; López CA; Derdeyn CA; Jones MS; Pinter A; Korber B; Gnanakaran S
    PLoS Comput Biol; 2016 Oct; 12(10):e1005094. PubMed ID: 27716795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A conservative domain shared by HIV gp120 and EIAV gp90: implications for HIV vaccine design.
    Li H; Zhang X; Fan X; Shen T; Tong X; Shen R; Shao Y
    AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1057-9. PubMed ID: 16379610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural analogue peptides of an HIV-1 GP120 T-helper epitope antagonize response of GP120-specific human CD4 T-cell clones.
    Fenoglio D; Li Pira G; Lozzi L; Bracci L; Saverino D; Terranova P; Bottone L; Lantero S; Megiovanni A; Merlo A; Manca F
    J Acquir Immune Defic Syndr; 2000 Jan; 23(1):1-7. PubMed ID: 10708050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen structure influences helper T-cell epitope dominance in the human immune response to HIV envelope glycoprotein gp120.
    Mirano-Bascos D; Tary-Lehmann M; Landry SJ
    Eur J Immunol; 2008 May; 38(5):1231-7. PubMed ID: 18398933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-neutralizing antibodies: epitope identification and significance for future vaccine.
    Robert-Guroff M
    Int Rev Immunol; 1990; 7(1):15-30. PubMed ID: 1722498
    [No Abstract]   [Full Text] [Related]  

  • 38. Mutational analysis of a principal neutralization domain of visna/maedi virus envelope glycoprotein.
    Haflidadóttir BS; Matthíasdóttir S; Agnarsdóttir G; Torsteinsdóttir S; Pétursson G; Andrésson ÓS; Andrésdóttir V
    J Gen Virol; 2008 Mar; 89(Pt 3):716-721. PubMed ID: 18272763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV gp120 epitope immunodominance in MRL/Ipr mice.
    Lombardi V; Rossi P; Romiti L; Mattei M; Mariani F; Poccia F; Colizzi V
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1081-2. PubMed ID: 1503821
    [No Abstract]   [Full Text] [Related]  

  • 40. Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.
    Ratto-Kim S; de Souza MS; Currier JR; Karasavvas N; Sidney J; Rolland M; Valencia-Micolta A; Madnote S; Sette A; Nitayaphan S; Pitisuttuthum P; Kaewkungwal J; Rerks-Ngarm S; O'Connell R; Michael N; Robb ML; Marovich M; Kim JH
    PLoS One; 2015; 10(2):e0115582. PubMed ID: 25665096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.